These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 28360528)

  • 1. The association of weight loss with patient experience and outcomes in a population of patients with type 2 diabetes mellitus prescribed canagliflozin.
    Gerlanc NM; Cai J; Tkacz J; Bolge SC; Brady BL
    Diabetes Metab Syndr Obes; 2017; 10():89-99. PubMed ID: 28360528
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CANadian CAnagliflozin REgistry: Patient-Reported Outcomes of Canagliflozin in the Treatment of Type 2 Diabetes Mellitus in Canadian Clinical Practice.
    Woo V; Bell A; Clement M; Noronha L; Tsoukas MA; Camacho F; Traina S; Georgijev N; Rose JB; Sorabji D; Bajaj HS
    Can J Diabetes; 2019 Oct; 43(7):464-471. PubMed ID: 31133438
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Health care provider experience with canagliflozin in real-world clinical practice: favorability, treatment patterns, and patient outcomes.
    Bolge SC; Flores NM; Huang S; Cai J
    Int J Gen Med; 2017; 10():177-187. PubMed ID: 28694704
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-Effectiveness Analysis of Canagliflozin 300 mg Versus Dapagliflozin 10 mg Added to Metformin in Patients with Type 2 Diabetes in the United States.
    Neslusan C; Teschemaker A; Willis M; Johansen P; Vo L
    Diabetes Ther; 2018 Apr; 9(2):565-581. PubMed ID: 29411292
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of canagliflozin on body weight and body composition in patients with type 2 diabetes over 104 weeks.
    Blonde L; Stenlöf K; Fung A; Xie J; Canovatchel W; Meininger G
    Postgrad Med; 2016 May; 128(4):371-80. PubMed ID: 27002421
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Canagliflozin: a sodium glucose co-transporter 2 inhibitor for the treatment of type 2 diabetes mellitus.
    Rosenthal N; Meininger G; Ways K; Polidori D; Desai M; Qiu R; Alba M; Vercruysse F; Balis D; Shaw W; Edwards R; Bull S; Di Prospero N; Sha S; Rothenberg P; Canovatchel W; Demarest K
    Ann N Y Acad Sci; 2015 Nov; 1358():28-43. PubMed ID: 26305874
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An evidence-based practice-oriented review focusing on canagliflozin in the management of type 2 diabetes.
    Messana JA; Schwartz SS; Townsend RR
    Vasc Health Risk Manag; 2017; 13():43-54. PubMed ID: 28255241
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bone effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus.
    Blevins TC; Farooki A
    Postgrad Med; 2017 Jan; 129(1):159-168. PubMed ID: 27894216
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-Effectiveness of Canagliflozin versus Sitagliptin as Add-on to Metformin in Patients with Type 2 Diabetes Mellitus in Mexico.
    Neslusan C; Teschemaker A; Johansen P; Willis M; Valencia-Mendoza A; Puig A
    Value Health Reg Issues; 2015 Dec; 8():8-19. PubMed ID: 29698175
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of Weight Loss and Medication Adherence Among Adults With Type 2 Diabetes Mellitus: SHIELD (Study to Help Improve Early evaluation and management of risk factors Leading to Diabetes).
    Grandy S; Fox KM; Hardy E;
    Curr Ther Res Clin Exp; 2013 Dec; 75():77-82. PubMed ID: 24465048
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Health-related quality of life association with weight change in type 2 diabetes mellitus: perception vs. reality.
    Grandy S; Fox KM; Bazata DD;
    Int J Clin Pract; 2013 May; 67(5):455-61. PubMed ID: 23574105
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Short-term outcomes of patients with Type 2 diabetes mellitus treated with canagliflozin compared with sitagliptin in a real-world setting.
    Shao YL; Yee KH; Koh SK; Wong YF; Yeoh LY; Low S; Sum CF
    Singapore Med J; 2018 May; 59(5):251-256. PubMed ID: 29022040
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The CANVAS Program: implications of canagliflozin on reducing cardiovascular risk in patients with type 2 diabetes mellitus.
    Carbone S; Dixon DL
    Cardiovasc Diabetol; 2019 May; 18(1):64. PubMed ID: 31138195
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of Sodium-glucose Cotransporter 2 Inhibitor Monotherapy on Weight Changes in Patients With Type 2 Diabetes Mellitus: a Bayesian Network Meta-analysis.
    Wang H; Yang J; Chen X; Qiu F; Li J
    Clin Ther; 2019 Feb; 41(2):322-334.e11. PubMed ID: 30711143
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of canagliflozin treatment in older subjects with type 2 diabetes mellitus: a randomized trial.
    Bode B; Stenlöf K; Sullivan D; Fung A; Usiskin K
    Hosp Pract (1995); 2013 Apr; 41(2):72-84. PubMed ID: 23680739
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A review of clinical efficacy and safety of canagliflozin 300 mg in the management of patients with type 2 diabetes mellitus.
    Prasanna Kumar KM; Ghosh S; Canovatchel W; Garodia N; Rajashekar S
    Indian J Endocrinol Metab; 2017; 21(1):196-209. PubMed ID: 28217522
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Canagliflozin, a novel SGLT2 inhibitor for treatment of type 2 diabetes.
    Nigro SC; Riche DM; Pheng M; Baker WL
    Ann Pharmacother; 2013 Oct; 47(10):1301-11. PubMed ID: 24259694
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Canagliflozin improves glycaemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin.
    Devineni D; Morrow L; Hompesch M; Skee D; Vandebosch A; Murphy J; Ways K; Schwartz S
    Diabetes Obes Metab; 2012 Jun; 14(6):539-45. PubMed ID: 22226086
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Link between body weight changes and metabolic parameters in drugs naïve subjects with type 2 diabetes treated with canagliflozin monotherapy.
    Kutoh E; Wada A; Kuto AN; Hayashi J; Kurihara R
    Hosp Pract (1995); 2020 Mar; 48(2):68-74. PubMed ID: 32098545
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.